| 23.03 0.68 (3.04%) | 01-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.17 | 1-year : | 36.93 |
| Resists | First : | 27.54 | Second : | 31.62 |
| Pivot price | 26.26  |
|||
| Supports | First : | 20.96 | Second : | 17.44 |
| MAs | MA(5) : | 23.8 |
MA(20) : | 26.35 |
| MA(100) : | 28.89 |
MA(250) : | 21.39 |
|
| MACD | MACD : | -1 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 0.8 |
D(3) : | 7.9 |
| RSI | RSI(14): 37.7  |
|||
| 52-week | High : | 54.29 | Low : | 9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTHS ] has closed above bottom band by 11.2%. Bollinger Bands are 5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.5 - 24.64 | 24.64 - 24.77 |
| Low: | 22.06 - 22.23 | 22.23 - 22.38 |
| Close: | 22.34 - 22.58 | 22.58 - 22.8 |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Thu, 15 Jan 2026
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics - Business Wire
Tue, 13 Jan 2026
Pelthos Therapeutics Secures $50 Million Venture Loan Financing - TipRanks
Tue, 13 Jan 2026
Pelthos Therapeutics Signs Venture Loan Agreement With Horizon Technology Finance - TradingView — Track All Markets
Tue, 13 Jan 2026
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - GlobeNewswire
Tue, 13 Jan 2026
New $50M boost backs first at-home treatment for kids’ skin virus - Stock Titan
Mon, 05 Jan 2026
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|